Persistence of high-risk human papillomavirus infection in a population-based cohort of Danish women

Journal of Medical Virology

Volumn 82, Issue 4, 2010, Pages 616-623

  Nielsen, Ann ^a   Kjaer, Susanne K ^a,b   Munk, Christian ^a   Osler, Merete ^c   Iftner, Thomas ^d  

^a INSTITUTE OF CANCER EPIDEMIOLOGY   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c GLOSTRUP UNIVERSITY HOSPITAL   (Denmark)

^d UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

Author keywords

Human papillomavirus; Randomly sampled women; Risk factors; Type specific persistence

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

ADULT; ARTICLE; CONTROLLED STUDY; FEMALE; GYNECOLOGICAL EXAMINATION; HIGH RISK PATIENT; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 58; INTERVIEW; INTRAUTERINE CONTRACEPTIVE DEVICE; MAJOR CLINICAL STUDY; PROSPECTIVE STUDY; SMOKING; VIRUS DETECTION; VIRUS INFECTION; VIRUS LOAD; VIRUS TYPING; WART VIRUS;

ADULT; COHORT STUDIES; DENMARK; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PROSPECTIVE STUDIES; RISK FACTORS; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS; HUMAN PAPILLOMAVIRUS TYPE 16;

EID: 77949345126     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21750     Document Type: Article

References (44)

1. Appleby P,Beral V, Berrington deGA,ColinD, Franceschi S,Goodill A, Green J, Peto J, Plummer M, Sweetland S. 2006. Carcinoma of the cervix and tobacco smoking: Collaborative reanalysis of individual data on 13,541 women with carcinoma of the cervix and 23,017 women without carcinoma of the cervix from 23 epidemiological studies. Int J Cancer 118:1481-1495.
2. Brisson J, Bairati I, Morin C, Fortier M, Bouchard C, Christen A, Bernard P, Roy M, Meisels A. 1996. Determinants of persistent detection of human papillomavirus DNA in the uterine cervix. J Infect Dis 173:794-799.
3. Castellsague X, DiazM, de Sanjose S, Munoz N,Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX. 2006. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: Implications for screening and prevention. J Natl Cancer Inst 98:303-315.
4. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Wacholder S, Tarone R, Burk RD. 2005. A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 191:1808-1816.
5. Giuliano AR, Sedjo RL, Roe DJ, Harri R, Baldwi S, Papenfuss MR, Abrahamsen M, Inserra P. 2002. Clearance of oncogenic human papillomavirus (HPV) infection: Effect of smoking (United States). Cancer Causes Control 13:839-846.
6. Gravitt PE, Burk RD, Lorincz A, Herrero R, Hildesheim A, Sherman ME,Bratti MC,Rodriguez AC, Helzlsouer KJ,Schiffman M.2003.A comparison between real-time polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA quantitation. Cancer Epidemiol Biomarkers Prev 12:477-484.
7. Green J, Berrington de GA, Smith JS, Franceschi S, Appleby P, Plummer M, Beral V. 2003. Human papillomavirus infection and use of oral contraceptives. Br J Cancer 88:1713-1720.
8. Hammouda D, Munoz N, Herrero R, Arslan A, Bouhadef A, Oublil M, Djedeat B, Fontaniere B, Snijders P, Meijer C, Franceschi S. 2005. Cervical carcinoma in Algiers, Algeria: Human papillomavirus and lifestyle risk factors. Int J Cancer 113:483-489.
9. Harrel FE Jr. 2001. Regression modeling strategies. New York (NY): Springer-Verlag. pp 16-26.
10. Hildesheim A, Schiffman MH, Gravitt PE, Glass AG, Greer CE, Zhang T, Scott DR, Rush BB, Lawler P, Sherman ME. 1994. Persistence of type-specific human papillomavirus infection among cytologically normal women. J Infect Dis 169:235-240.
11. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. 1998. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338:423-428.
12. Iftner T, Villa LL. 2003. Chapter 12: Human papillomavirus technologies. J Natl Cancer Inst Monogr 31:80-88.
13. Kjaer SK, van den Brule AJ, Bock JE, Poll PA, Engholm G, Sherman ME, Walboomers JM, Meijer CJ. 1996. Human papillomavirus - The most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 65:601-606.
14. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, Suntum M, Bock JE, Poll PA, Meijer CJ. 2002. Type specific persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous intraepithelial lesions in young women: Population based prospective follow up study. BMJ 325: 572.
15. Kjaer SK, Munk C, Winther JF, Jorgensen HO, Meijer CJ, van den Brule AJ. 2005. Acquisition and persistence of human papillomavirus infection in younger men: A prospective follow-up study among Danish soldiers. Cancer Epidemiol Biomarkers Prev 14:1528-1533.
16. Kjaer SK, Hogdall E, Frederiksen K, Munk C, Van den Brule A, Svare E, Meijer C, Lorincz A, Iftner T. 2006. The absolute risk of cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 10-year period. Cancer Res 66:10630-10636.
17. Klug SJ, Molijn A, Schopp B, Holz B, Iftner A, Quint W, Snijders JF, Petry KU, Kruger KS, Munk C, Iftner T. 2008. Comparison of the performance of different HPV genotyping methods for detecting genital HPV types. J Med Virol 80:1264-1274.
18. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D, Smith JS. 2008. Persistent human papillomavirus infection and cervical neoplasia: A systematic review and meta-analysis. Am J Epidemiol 15:123-137.
19. Kulmala SM, Shabalova IP, Petrovitchev N, Syrjanen KJ, Gyllensten UB, Johansson BC, Syrjanen SM. 2007. Type-specific persistence of high-risk human papillomavirus infections in the New Independent States of the former Soviet Union Cohort Study. Cancer Epidemiol Biomarkers Prev 16:17-22.
20. Lajous M, Mueller N, Cruz-Valdez A, Aguilar LV, Franceschi S, Hernandez-Avila M, Lazcano-Ponce E. 2005. Determinants of prevalence, acquisition, and persistence of human papillomavirus in healthy Mexican military men. Cancer Epidemiol Biomarkers Prev 14:1710-1716.
21. Li HQ, Thomas DB, Jin SK, Wu F. 2000. Tubal sterilization and use of an IUD and risk of cervical cancer. J Womens Health Gend Based Med 9:303-310.
22. Maucort-Boulch D, Plummer M, Castle PE, Demuth F, Safaeian M, et al. 2010. Predictors of human papillomavirus persistence among women with equivocal or mildly abnormal cytology. Int J Cancer 126: 684-691.
23. Molano M, Van den BA, Plummer M,Weiderpass E, Posso H, Arslan A, Meijer CJ,Munoz N, Franceschi S. 2003. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: A population-based, 5-year follow-up study. Am J Epidemiol 158:486-494.
24. Moscicki AB, Ellenberg JH, Farhat S, Xu J. 2004. Persistence of human papillomavirus infection in HIV-infected and -uninfected adolescent girls: Risk factors and differences, by phylogenetic type. J Infect Dis 190:37-45.
25. Moscicki AB, Schiffman M, Kjaer S, Villa LL. 2006. Chapter 5: Updating the natural history of HPV and anogenital cancer. Vaccine 24:S342-S351.
26. Munoz N,Hernandez-Suarez G, Mendez F,Molano M,Posso H,Moreno V, Murillo R, Ronderos M, Meijer C, Munoz A. 2009. Persistence of HPV infection and risk of high-grade cervical intraepithelial neoplasia in a cohort of Colombian women. Br J Cancer 100: 1184-1190.
27. Nielsen A, Kjaer SK, Munk C, Iftner T. 2008. Type-specific HPV infection and multiple HPV types: Prevalence and risk factor profile in nearly 12,000 younger and older danish women. Sex Transm Dis 35:276-282.
28. Perrons C, Jelley R, Kleter B, Quint W, Brink N. 2005. Detection of persistent high risk human papillomavirus infections with hybrid capture II and SPF10/LiPA. J Clin Virol 32:278-285.
29. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM. 2007. A 2-year prospective study of human papillomavirus persistence among women with a cytological diagnosis of atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J Infect Dis 195:1582-1589.
30. Richardson H, Abrahamowicz M, Tellier PP, Kelsall G, du Berger R, Ferenczy A, Coutlee F, Franco EL. 2005. Modifiable risk factors associated with clearance of type-specific cervical human papillomavirus infections in a cohort of university students. Cancer Epidemiol Biomarkers Prev 14:1149-1156.
31. Samoff E, Koumans EH, Markowitz LE, Sternberg M, Sawyer MK, Swan D, Papp JR, Black CM, Unger ER. 2005. Association of Chlamydia trachomatis with persistence of high-risk types of human papillomavirus in a cohort of female adolescents. Am J Epidemiol 162:668-675.
32. Sanjosé deS, Diaz M, Castellsague X, Clifford G, Bruni L, Munoz N, Bosch FX. 2007.Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis 7:453-459.
33. Schiffman M, Herrero R, Desalle R, Hildesheim A, Wacholder S, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Hutchinson M, Wright TC, Solomon D, Chen Z, Schussler J, Castle PE, Burk RD. 2005. The carcinogenicity of human papillomavirus types reflects viral evolution. Virology 337:76-84.
34. Schiffman M, Castle PE, Jeronimo J,Rodriguez AC, Wacholder S. 2007. Human papillomavirus and cervical cancer. Lancet 370:890-907.
35. Schlecht NF, Kulaga S, Robitaille J, Ferreira S, Santos M, Miyamura RA, Duarte-Franco E, Rohan TE, Ferenczy A, Villa LL, Franco EL. 2001. Persistent human papillomavirus infection as a predictor of cervical intraepithelial neoplasia. JAMA 286:3106-3114.
36. Shew ML, Fortenberry JD, Tu W, Juliar BE, Batteiger BE, Qadadri B, Brown DR. 2006. Association of condom use, sexual behaviors, and sexually transmitted infections with the duration of genital human papillomavirus infection among adolescent women. Arch Pediatr Adolesc Med 160:151-156.
37. Silins I, Ryd W, Strand A,Wadell G, Tornberg S, Hansson BG, Wang X, Arnheim L, Dahl V, Bremell D, Persson K, Dillner J, Rylander E. 2005. Chlamydia trachomatis infection and persistence of human papillomavirus. Int J Cancer 116:110-115.
38. Sycuro LK, Xi LF, Hughes JP, Feng Q, Winer RL, Lee SK, O'Reilly S, Kiviat NB, Koutsky LA. 2008. Persistence of genital human papillomavirus infection in a long-term follow-up study of female university students. J Infect Dis 198:971-978.
39. Syrjanen S, Shabalova I, Petrovichev N, Kozachenko V, Zakharova T, Pajanidi J,Podistov J, Chemeris G, Sozaeva L, Lipova E, Tsidaeva I, Ivanchenko O, Pshepurko A, Zakharenko S, Nerovjna R, Kljukina L, Erokhina O, Branovskaja M, Nikitina M, Grunberga V, Grunberg A, Juschenko A, Cintorino M, Santopietro R, Tosi P, Syrjanen K. 2005. Factors predicting persistence of high-risk human papillomavirus (HPV) infections in women prospectively followed-up in three New Independent States (NIS) of the former Soviet Union. Eur J Gynaecol Oncol 26:491-498.
40. Trottier H, Mahmud S, Prado JC, Sobrinho JS, Costa MC, Rohan TE, Villa LL, Franco EL. 2008. Type-specific duration of human papillomavirus infection: Implications for human papillomavirus screening and vaccination. J Infect Dis 197:1436-1447.
41. van Duin M, Snijders PJ, Schrijnemakers HF, Voorhorst FJ, Rozendaal L, Nobbenhuis MA, van den Brule AJ, Verheijen RH, Helmerhorst TJ, Meijer CJ. 2002. Human papillomavirus 16 load in normal and abnormal cervical scrapes: An indicator of CIN II/III and viral clearance. Int J Cancer 98:590-595.
42. Wang SS, Hildesheim A. 2003. Chapter 5: Viral and host factors in human papillomavirus persistence and progression. J Natl Cancer Inst Monogr 31:35-40.
43. Wang SS, Schiffman M,Herrero R, Carreon J, Hildesheim A,Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Clayman B, Burk RD, Viscidi RP. 2004. Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000women in Costa Rica. Br JCancer 91:1269-1274.
44. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P, Yates M, Rollason TP, Young LS. 2001. Natural history of cervical human papillomavirus infection in young women: A longitudinal cohort study. Lancet 357:1831-1836.